BBOT Stock Slides as Investors Price a Smaller Opportunity
BBOT dropped ~38% in two days. Stifel, Leerink, Canaccord, and JPMorgan lowered targets but did not downgrade ratings. JPMorgan sees a disconnect vs pipeline value.
/ 2 items
BBOT dropped ~38% in two days. Stifel, Leerink, Canaccord, and JPMorgan lowered targets but did not downgrade ratings. JPMorgan sees a disconnect vs pipeline value.
BBOT receives U.S. FDA Fast Track Designation for BBO-11818, its pan-KRAS inhibitor for advanced KRAS-mutant pancreatic cancer. Phase 1 data expected H2 2026.